Table 2.
Characteristics of patients suspected of pertussis in Perú during 2012
| PCR-negative n = 649 (%) | PCR-positive n = 191 (%) | P value | |
|---|---|---|---|
| Gender | |||
| Male | 300 (46.2) | 90 (47.1) | 0.827 |
| Female | 349 (53.8) | 101 (52.9) | |
| Vaccine | |||
| Yes | 265 (40.8) | 82 (42.9) | 0.81 |
| No | 182 (28.0) | 59 (30.9) | |
| No data | 202 (31.1) | 50 (26.2) | |
| Vaccine dosesa | |||
| 0–3 doses | 331 (74.0) | 133 (94.3) | <0.00001* |
| 4–5 doses | 116 (26.0) | 8 (5.7) | |
| Clinical symptoms | |||
| Persistent cough | 460 (70.9) | 160 (83.8) | 0.00037* |
| Paroxysmal cough | 416 (64.1) | 147 (77.0) | 0.00089* |
| Vomiting after coughing | 97 (14.9) | 114 (59.7) | <0.00001* |
| Stridor | 177 (27.3) | 71 (37.2) | 0.0084* |
| Apnea | 147 (22.7) | 59 (30.9) | 0.02 |
| Cough (days) | |||
| 1–6 | 132 (20.3) | 43 (22.5) | 0.51 |
| 7–12 | 93 (14.3) | 46 (24.1) | 0.0014* |
| 13–15 | 70 (10.8) | 39 (20.4) | 0.0005* |
| > 20 | 68 (10.5) | 12 (6.3) | 0.082 |
| No cough | 286 (44.1) | 51 (26.7) | |
| Hospitalization | |||
| Yes | 113 (17.4) | 67 (35.1) | <0.00001* |
| No | 363 (55.9) | 81 (42.4) | |
| Not indicated | 173 (26.7) | 43 (22.5) | |
| Antibiotica | |||
| Yes | 197 (41.0) | 100 (52.4) | − |
| Azithromycin | 29 (14.7) | 30 (30.0) | − |
| Erythromycin | 56 (28.4) | 25 (25.0) | − |
| Penicillins | 54 (27.4) | 22 (22.0) | − |
| Others | 58 (29.4) | 23 (23.0) | − |
| Antibiotic (days of treatment)a | − | ||
| 1–3d | 71 (10.9) | 31 (16.2) | − |
| 4–6d | 28 (4.3) | 16 (8.4) | − |
| ≥ 7d | 17 (2.6) | 14 (7.3) | − |
| Not indicated | 81 (12.5) | 39 (20.4) | − |
| Etiology | − | ||
| B. pertussis | 0 (0) | 145 (75.9) | − |
| B. parapertussis | 0 (0) | 2 (1.0) | − |
| Bordetella sp. | 0 (0) | 44 (23.0) | − |
*Chi-square (X 2) test (p <0.05)
aPercentages were calculated only in the population known to have been vaccinated or only in the recipients of an antibiotic
Of the total of 840 pertussis-suspected cases reported in 2012 in Perú, only 3 were treated with Cotrimoxazol